Invega (paliperidone) Extended-Release Tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)   March 2016 CONTRAINDICATIONS RISPERDAL/RISPERDAL CONSTA/INVEGA(s) is contraindicated in patients with a known...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts